

Brandes Investment Partners
European Equity Strategy Notes
Fourth Quarter 2022 (October 1 – December 31, 2022)

The Brandes European Equity Strategy rose 23.71% net of fees and 23.92% gross of fees, outperforming its benchmark, the MSCI Europe Index, which increased 19.35% in the fourth quarter, and the MSCI Europe Value Index, which rose 22.15%.

Annualized total return as of December 31, 2022	1-year	5-year	10-year
Brandes European Equity Composite (net)	-9.84%	1.37%	5.23%
Brandes European Equity Composite (gross)	-9.21%	2.03%	5.93%
MSCI Europe Index	-15.06%	1.87%	4.58%

Past performance is not a guarantee of future results. One cannot invest directly in an index. Returns include reinvestment of all dividends and are reduced by any applicable foreign withholding taxes, without provisions for income taxes, if any. Please refer to the GIPS® Report for additional information.

Positive Contributors

Value outperformance during the quarter provided a tailwind for the strategy. At the stock level, the strongest performers included several bank holdings that have continued to benefit from the global rise in interest rates, such as Austria-based **Erste Group**, Italy-based **Intesa Sanpaolo**, and Ireland-based **AIB Group**.

A variety of cyclical businesses also aided returns as they rose more than the broader market (MSCI Europe). These included Germany's **HeidelbergCement**, U.K.-based **Rolls-Royce**, and French advertising agency **Publicis**. Rolls-Royce's shares rose on news that its engines would be used on the next-generation fleet replacing the Black Hawk helicopters, which currently use legacy GE engines.

Several of our consumer staples holdings (e.g., U.K.-based retailers **J Sainsbury** and **Marks & Spencer**) did well despite the fact that the sector represented one of the weakest performing areas within the benchmark. Other contributors included health care holdings Ireland-based **Avadel Pharmaceuticals** and Spain-based **Grifols**.

Performance Detractors

Amid a rising overall market, the largest detractors included Switzerland-based **Credit Suisse** and Dutch health care conglomerate **Koninklijke Philips**.

Philips saw its shares tumble as it issued a profit warning due to the continued impact of supply chain problems.

Credit Suisse declined after announcing a significant restructuring plan and a capital raise. If successful, the restructuring should position the company well longer term, in our view, as it will allow the business to focus more on its strong wealth management and domestic Swiss bank franchises. This being said, a meaningful execution risk exists, and while the current valuation is attractive, we will continue to monitor the company's progress.

Other detractors included smaller-cap companies such as food products company **Greencore**, uranium company **Yellow Cake**, and U.K.-based currency manufacturer **De La Rue**.

Select Activity in the Quarter

The investment committee initiated a position in U.K.-based medical device and technology company **Smith & Nephew** (S&N) while divesting our position in Turkish confectionary company **Ulker Biskuvi Sanayi**.

Smith & Nephew is a leading global medical device company with a focus on orthopedics (knee and hip replacements), sports medicine, ENT (ear, nose, and throat), and wound management markets. The company has seen its share price decline over the last two years as the impact of Covid-19 has delayed many patients' elective but important medical procedures, such as orthopedic surgeries like knee and hip replacements. We expect the company should be able to benefit from a recovery in demand as elective procedures recover. Additionally, both orthopedic devices and sports

medicine technology (arthroscopic technologies used for joint repair) have fairly high switching costs due to the learning curve for surgeons using these devices, which helps companies in these verticals maintain their market shares.

More recently, S&N has been impacted by inflationary pressures from its supply chain, which will likely hurt its short-term margins. However, over the long term, we believe the company offers an attractive investment opportunity in light of long-term tailwinds such as an aging population and increasing obesity rates, which could increase demand for orthopedic procedures, as well as the company's growing exposure in emerging markets. Additionally, the company has a strong balance sheet and a strong history of generating free cash flow to support its dividend and share repurchases, which could prove to be more defensive in a difficult economic environment.

The committee divested its holding in Turkish confectionary company Ulker as it performed well this year and reached our estimate of its intrinsic value.

Year-to-Date Briefing

The Brandes European Equity Strategy fell 9.84% net of fees and 9.21% gross of fees, outperforming its benchmark, the MSCI Europe Index, which declined 15.06% for the year ended December 31, 2022, and underperforming the MSCI Europe Value Index, which dropped 7.17%.

The largest drivers of outperformance relative to the benchmark were our overweight positions in energy companies (the best-performing sector in the benchmark) and our underweight in the technology sector (one of the worst-performing sectors in the benchmark) as well as the performance of several of our industrial holdings. Geographically, holdings in France helped returns the most, led by France-based **Societe BIC**. The strongest contributors included several holdings mentioned earlier, such as AIB Group and Avadel Pharmaceuticals. Other stronger contributors included oil services company **TechnipFMC**, construction company **Balfour Beatty**, defense company **Leonardo**, and Spanish bank **CaixaBank**.

Major detractors included our holdings in Russia from early in the year, namely **Surgutneftegas**, **Lukoil**, and **Mobile Telesystems**. These three holdings more than accounted for the strategy's underperformance vs. the value index as Russia was not included in the MSCI Europe Value Index. Additional detractors included several holdings mentioned earlier, such as Credit Suisse, Greencore, and Koninklijke Philips. **Telecom Italia** also detracted from returns as its stock declined early in the year after private equity firm KKR withdrew its offer to acquire the company.

Current Positioning

As of December 31, 2022, the Brandes European Equity Strategy held key overweight positions in communication services, financials, and consumer staples, while maintaining significantly lower allocations to consumer discretionary, technology, and industrials than the benchmark.

The relative performance for value (MSCI Europe Value) vs. the benchmark (MSCI Europe) along with a significant return dispersion among sectors, has helped create new value opportunities for us while also enabling us to pare select holdings that have neared our estimates of intrinsic value. We have pared some of our stronger performing areas such as consumer staples and energy, a sector we are now roughly equal weight to the benchmark. Meanwhile, we have started to find more opportunities in technology-related companies and financials. Although we remained underweight technology, our underweight has declined as the benchmark allocation decreased due to the sector's underperformance and our allocation increased.

On a geographic basis, the portfolio's largest allocations continued to be in France and the United Kingdom. The strategy remained underweight to Germany and Switzerland, as well as to companies domiciled in the Nordics. We believe the differences between our portfolio and the benchmark continue to make it an attractive complement to index-tracking or growth-oriented alternatives.

A variety of headwinds continue to face European stocks today, ranging from elevated inflation, slowing economic growth and recession concerns to energy risk and political as well as regulatory uncertainties. Nonetheless, we believe European stocks in general—and our portfolio in particular—offer an attractive long-term risk/reward tradeoff at today's valuation

levels. Even after their relative performance this year, European value stocks continue to trade in the highest quintile of discount levels to the broader European market on a variety of valuation metrics (e.g., forward price/earnings, price/cash flows, enterprise value/sales). Looking ahead to this year and beyond, we remain optimistic about the European Equity Strategy's prospects, given its history of outperforming the MSCI Europe Index during periods of strong value performance. We believe our portfolio trades at an attractive absolute valuation level relative to the individual holdings' fundamentals/prospects and we remain excited about its potential.

Enterprise Value: Market capitalization plus debt, minority interest and preferred shares, minus total cash and cash equivalents.

Enterprise Value/Sales: Enterprise value divided by annual sales.

Free Cash Flow: Total cash flow from operations less capital expenditures.

Forward Price/Earnings: Price per share divided by earnings per share expected over the next 12 months or next fiscal year.

Price/Cash Flow (P/CF): Price per share divided by cash flow per share.

The MSCI Europe Index with net dividends captures large and mid cap representation of developed market countries in Europe.

The MSCI Europe Value Index captures large and mid cap securities across developed Europe exhibiting value style characteristics, defined using book value to price, 12-month forward earnings to price, and dividend yield.

MSCI has not approved, reviewed or produced this report, makes no express or implied warranties or representations and is not liable whatsoever for any data in the report. You may not redistribute the MSCI data or use it as a basis for other indices or investment products.

Diversification does not assure a profit or protect against a loss in a declining market.

The foregoing Quarterly Commentary reflects the thoughts and opinions of Brandes Investment Partners® exclusively and is subject to change without notice. The information provided in the commentary should not be considered a recommendation to purchase or sell any particular security. It should not be assumed that any security transactions, holdings or sectors discussed were or will be profitable, or that the investment recommendations or decisions we make in the future will be profitable or will equal the investment performance discussed herein. International and emerging markets investing is subject to certain risks such as currency fluctuation and social and political changes; such risks may result in greater share price volatility. There is no assurance that any securities discussed herein will remain in an account's portfolio at the time you receive this report or that the securities sold have not been repurchased. The actual characteristics with respect to any particular account will vary based on a number of factors including but not limited to: (i) the size of the account; (ii) investment restrictions applicable to the account, if any; and (iii) market exigencies at the time of investment. Unlike bonds issued or guaranteed by the U.S. government or its agencies, stocks and other bonds are not backed by the full faith and credit of the United States. Stock and bond prices will experience market fluctuations. Please note that the value of government securities and bonds in general have an inverse relationship to interest rates. Bonds carry the risk of default, or the risk that an issuer will be unable to make income or principal payment. There is no assurance that private guarantors or insurers will meet their obligations. The credit quality of the investments in the portfolio is not a guarantee of the safety or stability of the portfolio. Investments in Asset Backed and Mortgage Backed Securities include additional risks that investors should be aware of such as credit risk, prepayment risk, possible illiquidity and default, as well as increased susceptibility to adverse economic developments. Securities of small companies generally experience more volatility than mid and large sized companies. Although the statements of fact and data in this report have been obtained from, and are based upon, sources that are believed to be reliable, we cannot guarantee their accuracy, and any such information may be incomplete or condensed. Strategies discussed are subject to change at any time by the investment manager in its discretion due to market conditions or opportunities. The Brandes investment approach tends to result in portfolios that are materially different than their benchmarks with regard to characteristics such as risk, volatility, diversification, and concentration. Please note that all indices are unmanaged and are not available for direct investment. Past performance is not a guarantee of future results. No investment strategy can assure a profit or protect against loss. Market conditions may impact performance. The performance results presented were achieved in particular market conditions which may not be repeated. Moreover, the current market volatility and uncertain regulatory environment may have a negative impact on future performance. The margin of safety for any security is defined as the discount of its market price to what the firm believes is the intrinsic value of that security. The declaration and payment of shareholder dividends are solely at the discretion of the issuer and are subject to change at any time.

United States: Issued by Brandes Investment Partners, L.P., 4275 Executive Square, 5th Floor, La Jolla, CA 92037.

Singapore/Asia: FOR INSTITUTIONAL/ACCREDITED INVESTOR USE ONLY. Issued by Brandes Investment Partners (Asia) Pte Ltd., The Gateway West, 150 Beach Road, #35-51, Singapore 189720. Company Registration Number 201212812M. ABRN:164 952 710. This document is for "institutional investors" or "accredited investors" as defined under the Securities and Futures Act, Chapter 289 of Singapore and may not be distributed to any other person. This document is being provided for information purposes only. Incorporated in Singapore in 2012, Brandes Investment Partners (Asia) Pte Ltd (Brandes Asia) provides portfolio management services to clients in Asia (as permitted under local law). Brandes Investment Partners, L.P., a U.S. registered investment adviser and a sister entity to Brandes Asia, provides research, portfolio construction and other support to Brandes Asia.